Insulet Corporation reported $3.05B of revenue over the trailing twelve months, +29% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $3.05B (to Q2 2026). Net income: $375M, trailing twelve months to Q2 2026. Free cash flow: $294M, trailing twelve months to Q2 2026. Operating margin: 17%, trailing twelve months to Q2 2026.

PODDInsulet Corporation

Healthcare

$135.27-59% 1Y

$135.27

$130.5052 weeks$346.36

PODD as reported

Insulet Corporation reported $3.05B of revenue over the trailing twelve months, +29% on the year before. 11 reported series are charted on this page, each one as filed.

$3.05B

Revenue, trailing twelve months · to Q2 2026 · +29% against the twelve months before

Net income: $375M
Net income · +59% year on year · trailing twelve months to Q2 2026
Free cash flow: $294M
Free cash flow · −27% year on year · trailing twelve months to Q2 2026
Operating margin: 17%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PODD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$3.05B	+29%	Q2 2026
Net income	$375M	+59%	Q2 2026
EPS	$5.34	+63%	Q2 2026
Gross margin	71%	n/a	Q2 2026
Operating margin	17%	n/a	Q2 2026
Net margin	12%	n/a	Q2 2026
ROE	21%	n/a	Q2 2026
ROA	9.5%	n/a	Q2 2026
ROIC	22%	n/a	Q2 2026
Free cash flow	$294M	−27%	Q2 2026
P/E	25.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.